HPV vaccination crisis in Japan

Sharon J. B. Hanley; Eiji Yoshioka; Yoshiya Ito; Reiko Kishi

doi:10.1016/S0140-6736(15)61152-7

HPV vaccination crisis in Japan

Sharon J. B. Hanley^* (Corresponding Author), Eiji Yoshioka, Yoshiya Ito, Reiko Kishi

^*Corresponding author for this work

Applied Health Sciences

Research output: Contribution to journal › Letter › peer-review

254 Citations (Scopus)

Abstract

Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media.1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use.2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan.

Original language	English
Pages (from-to)	2571
Number of pages	1
Journal	Lancet
Volume	385
Issue number	9987
Early online date	25 Jun 2015
DOIs	https://doi.org/10.1016/S0140-6736(15)61152-7
Publication status	Published - 27 Jun 2015

Bibliographical note

We thank Keisuke Tamori and Julia Brotherton for their advice.

SJBH is part of the executive board of the People's Campaign Against Female Cancers (PCAF) and a committee member of the Japanese Expert Board for the Eradication of Cervical Cancer. SJBH reports lecture fees from Japan Vaccine and the Japanese Expert Board for the Eradication of Cervical Cancer. PCAF and the Japanese Expert Board for the Eradication of Cervical Cancer have received funding from Japan Vaccine and Merck Sharp and Dohme. EY, YI, and RK declare no competing interests.

Keywords

Female
Humans
Adolescent
Child
Japan
Mass Screening/organization & administration/statistics & numerical data
Mothers/statistics & numerical data
Papillomavirus Vaccines/*administration & dosage/adverse effects
Patient Acceptance of Health Care/*statistics & numerical data
Uterine Cervical Neoplasms/prevention & control
Vaccination/*statistics & numerical data

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(15)61152-7Licence: Unspecified

Cite this

@article{bda3954ec14e4d4a8bd92b0e7daf0d6b,

title = "HPV vaccination crisis in Japan",

abstract = "Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media.1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use.2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan.",

keywords = "Female, Humans, Adolescent, Child, Japan, Mass Screening/organization & administration/statistics & numerical data, Mothers/statistics & numerical data, Papillomavirus Vaccines/*administration & dosage/adverse effects, Patient Acceptance of Health Care/*statistics & numerical data, Uterine Cervical Neoplasms/prevention & control, Vaccination/*statistics & numerical data",

author = "Hanley, {Sharon J. B.} and Eiji Yoshioka and Yoshiya Ito and Reiko Kishi",

note = "We thank Keisuke Tamori and Julia Brotherton for their advice. SJBH is part of the executive board of the People's Campaign Against Female Cancers (PCAF) and a committee member of the Japanese Expert Board for the Eradication of Cervical Cancer. SJBH reports lecture fees from Japan Vaccine and the Japanese Expert Board for the Eradication of Cervical Cancer. PCAF and the Japanese Expert Board for the Eradication of Cervical Cancer have received funding from Japan Vaccine and Merck Sharp and Dohme. EY, YI, and RK declare no competing interests.",

year = "2015",

month = jun,

day = "27",

doi = "10.1016/S0140-6736(15)61152-7",

language = "English",

volume = "385",

pages = "2571",

journal = "Lancet",

issn = "1474-547X",

publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",

number = "9987",

}

TY - JOUR

T1 - HPV vaccination crisis in Japan

AU - Hanley, Sharon J. B.

AU - Yoshioka, Eiji

AU - Ito, Yoshiya

AU - Kishi, Reiko

N1 - We thank Keisuke Tamori and Julia Brotherton for their advice. SJBH is part of the executive board of the People's Campaign Against Female Cancers (PCAF) and a committee member of the Japanese Expert Board for the Eradication of Cervical Cancer. SJBH reports lecture fees from Japan Vaccine and the Japanese Expert Board for the Eradication of Cervical Cancer. PCAF and the Japanese Expert Board for the Eradication of Cervical Cancer have received funding from Japan Vaccine and Merck Sharp and Dohme. EY, YI, and RK declare no competing interests.

PY - 2015/6/27

Y1 - 2015/6/27

N2 - Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media.1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use.2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan.

AB - Free vaccination against the human papillomavirus (HPV) began in December, 2010, for Japanese girls aged 12–16 years and since April, 2013, the vaccine was included in the national immunisation programme. However, in June, 2013, the Japanese Ministry of Health, Labour, and Welfare suspended proactive recommendations for the HPV vaccine after unconfirmed reports of adverse events following vaccination appeared in the media.1 In January, 2014, the Vaccine Adverse Reactions Review Committee investigating these adverse events concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events after vaccination, but they still did not reinstate proactive recommendations for its use.2 We report the resulting effects of such a decision by presenting data from Sapporo, a city of 2 million people in northern Japan.

KW - Female

KW - Humans

KW - Adolescent

KW - Child

KW - Japan

KW - Mass Screening/organization & administration/statistics & numerical data

KW - Mothers/statistics & numerical data

KW - Papillomavirus Vaccines/administration & dosage/adverse effects

KW - Patient Acceptance of Health Care/statistics & numerical data

KW - Uterine Cervical Neoplasms/prevention & control

KW - Vaccination/statistics & numerical data

U2 - 10.1016/S0140-6736(15)61152-7

DO - 10.1016/S0140-6736(15)61152-7

M3 - Letter

SN - 1474-547X

VL - 385

SP - 2571

JO - Lancet

JF - Lancet

IS - 9987

ER -

HPV vaccination crisis in Japan

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this